Dermira, Inc. (DERM) Given Average Recommendation of “Hold” by Analysts
Shares of Dermira, Inc. (NASDAQ:DERM) have received an average rating of “Hold” from the eleven analysts that are currently covering the firm, Marketbeat.com reports. Five investment analysts have rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $43.80.
Several equities research analysts have weighed in on DERM shares. BidaskClub raised Dermira from a “hold” rating to a “buy” rating in a research report on Tuesday, June 27th. Needham & Company LLC reaffirmed a “buy” rating and set a $46.00 price target on shares of Dermira in a research report on Tuesday, July 18th. Evercore ISI started coverage on Dermira in a research report on Thursday, June 29th. They set an “outperform” rating and a $48.00 price target on the stock. Zacks Investment Research downgraded Dermira from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Finally, Cantor Fitzgerald started coverage on Dermira in a research report on Thursday, June 22nd. They set an “overweight” rating and a $45.00 price target on the stock.
Dermira (NASDAQ DERM) traded up 2.57% during trading on Friday, reaching $23.12. The company had a trading volume of 132,981 shares. Dermira has a 52 week low of $21.35 and a 52 week high of $38.75. The stock has a 50 day moving average price of $28.28 and a 200 day moving average price of $30.71. The firm’s market capitalization is $961.58 million.
Dermira (NASDAQ:DERM) last released its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by $0.04. Dermira had a negative net margin of 408.50% and a negative return on equity of 31.66%. The firm had revenue of $1.07 million during the quarter, compared to analyst estimates of $1 million. Analysts predict that Dermira will post ($4.17) earnings per share for the current year.
In other Dermira news, SVP Christopher M. Griffith sold 1,312 shares of the stock in a transaction dated Monday, May 15th. The stock was sold at an average price of $27.07, for a total transaction of $35,515.84. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Thomas G. Wiggans sold 5,000 shares of the stock in a transaction dated Friday, June 2nd. The stock was sold at an average price of $27.52, for a total value of $137,600.00. The disclosure for this sale can be found here. Insiders have sold a total of 16,812 shares of company stock worth $482,231 over the last ninety days. 13.30% of the stock is owned by insiders.
Several large investors have recently bought and sold shares of DERM. BNP Paribas Arbitrage SA boosted its stake in Dermira by 2,220.7% in the second quarter. BNP Paribas Arbitrage SA now owns 4,154 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 3,975 shares during the period. SG Americas Securities LLC boosted its stake in Dermira by 66.8% in the second quarter. SG Americas Securities LLC now owns 5,503 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 2,203 shares during the period. KCG Holdings Inc. acquired a new stake in Dermira during the first quarter worth approximately $215,000. Legal & General Group Plc boosted its stake in Dermira by 16.3% in the first quarter. Legal & General Group Plc now owns 6,861 shares of the biopharmaceutical company’s stock worth $236,000 after buying an additional 963 shares during the period. Finally, Tocqueville Asset Management L.P. acquired a new stake in Dermira during the first quarter worth approximately $256,000. Hedge funds and other institutional investors own 84.57% of the company’s stock.
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.